VYNE Q3 net loss $9.5M; VYN201 Phase 1a/b enrollment imminent; FMX114 strategy under review

VYNE Therapeutics Inc.

2022-Q3 EPS reported -$0.23 revenue$471,000

Q3 2022 net loss $9.5M vs $21.3M; operating loss $9.3M vs $14.3M year-over-year.
IND cleared for VYN201; first patient expected in Phase 1a/b vitiligo trial Nov. 2022 with topline data H1 2023.
FMX114 Phase 2a missed primary endpoint at week 4 but statistically superior at weeks 1-3; evaluating strategy for moderate-to-severe AD.
VYN202 oral BETi program progressing with Tay Therapeutics toward lead candidate selection.
Corporate presentation posted; cash position not separately disclosed in released results.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

VYNE Therapeutics Inc. reported three and nine months ended September 30, 2022 results: net income Net loss (GAAP) $ (9,459 ) $ (21,285 ) $ (13,265 ) $ (61,759 ).

Period: three and nine months ended September 30, 2022
Net income: Net loss (GAAP) $ (9,459 ) $ (21,285 ) $ (13,265 ) $ (61,759 )
Result: reported results

Exact text from the filing

VYNE Therapeutics Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

VYNE Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-117150

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.